This ruling has zero material impact on JNJ's operations, cash flows, or legal exposure. Xarelto product liability litigation has been ongoing for years with thousands of federal cases previously resolved or managed through MDL 2592. A single plaintiff's pro se dismissal on procedural grounds is not a read-through for broader Xarelto liability. No trader response warranted.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $229.12entry
- T+1 · 6mo ago +1.07%α +0.88% · $231.58
- T+5 · 6mo ago +0.95%α −0.29% · $231.29
- T+20 · 5mo ago +2.22%α +2.26% · $234.20
- T+60 · 3mo ago +13.63%α +8.89% · $260.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The Ninth Circuit affirmed the district court's dismissal of a product liability case against Janssen (JNJ subsidiary) and Bayer over Xarelto. The ruling was on procedural grounds, a child cannot bring loss-of-parental-consortium claims under California law, and a non-attorney guardian cannot prosecute pro se. The case was dismissed with no damages, no injunction, and no liability finding against JNJ. This is a complete win for JNJ on a routine, immaterial matter.
Court Ruling Details
Key Facts
- Ninth Circuit affirmed dismissal of Hu v. Janssen over Xarelto injury claims
- Loss of consortium claim dismissed with prejudice under California law (Borer v. American Airlines)
- Remaining claims dismissed without prejudice because plaintiff, as non-attorney guardian, cannot litigate pro se
- No damages, no injunction, no liability finding against Janssen or Bayer
- Case is a routine procedural win for JNJ, no material financial exposure
Financial Impact
None, no damages awarded, no liability found, no ongoing exposure. Case was dismissed entirely on procedural grounds.
Risk Factors
- Xarelto litigation broadly has been materially resolved, no systemic risk from this case
- No appeal possible on the loss-of-consortium claim (affirmed); other claims dismissed without prejudice but plaintiff lacks counsel to refile
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-tus9vruz-JNJ |
Track record
21 reports on JNJ
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers